Whitepapers
Nitrosamines Analysis
Since the FDA’s discovery of nitrosamines impurities, which led to the voluntary recall of valsartan in 2018, the pharmaceutical industry has undertaken a thorough investigation of this class of compounds to ensure patient safety. Since nitrosamines are a class of organic compounds identified as probable human carcinogens, the potential presence of these compounds in drug ... Nitrosamines Analysis